SCHEMBL15925824

SCHEMBL15925824

CCc1cc(N2CCNCC2)cc2c1Nc1ccc(C)cc1S2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 5/20 0.40
MAPT P10636 5/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
GAA P10253 3/20 0.38
ALOX12 P18054 1/20 0.38
EPHX2 P34913 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
ALOX15 P16050 2/20 0.34
HSD17B10 Q99714 2/20 0.34
MAPK1 P28482 1/20 0.34
ALDH1A1 P00352 2/20 0.34
USP2 O75604 1/20 0.34
POLB P06746 1/20 0.34
HTR1A P08908 4/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15925816 0.91 ADRB1 (0.41) ADRB1MAPTMEN1KMT2AGAA
SCHEMBL15909115 0.85 TDP1 (0.33) ADRB1MAPTMEN1KMT2AGAA
SCHEMBL15875839 0.81 ADRB1 (0.35) ADRB1MAPTALDH1A1POLBHTR1A
SCHEMBL15948289 0.80 CHRNB2 (0.34) ADRB1GUSB
SCHEMBL15925825 0.80 MEN1 (0.43) MAPTMEN1KMT2AGAAALOX12
SCHEMBL13386113 0.79 MAPT (0.44) MAPTMEN1KMT2AHSD17B10MAPK1
SCHEMBL2594059 0.76 MEN1 (0.39) ADRB1MAPTMEN1KMT2AGAA
SCHEMBL15948246 0.76 CHRNB2 (0.34) ADRB1MAPTALDH1A1HTR1AHTR6
SCHEMBL18913258 0.73 ADRB1 (0.41) ADRB1MAPTALDH1A1HTR1AHTR6
Hydrochloric Acid SCHEMBL13386325 0.72 MEN1 (0.36) ADRB1MAPTMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease Prosetta Antiviral, Inc. 2017-06-01 US disclosed
US-9382221-B2 Compounds, compositions, and methods for treating alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2016-07-05 US disclosed
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE Prosetta Antiviral, Inc. 2014-10-23 US disclosed
US-8796448-B1 Compounds, compositions, and methods for treating Alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2014-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease PSEN1, APP, PSEN2 ADRB1 1509/4885MAPT 11/4885MEN1 1540/4885
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE PSEN1, APP, PSEN2 ADRB1 1509/4885MAPT 11/4885MEN1 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.